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Background: Drug-Related Problems (DRPs) commonly occur among type 2 diabetes mellitus (T2DM) patients.
However, few studies have been performed on T2DM patients with dyslipidemia. This purpose of this study was to
assess drug-related problems (DRPs) and factors associated with its occurrence.
Methods: The retrospective study involved 208 T2DM in-patients and out-patients with dyslipidemia, and was
conducted at a tertiary hospital in Malaysia from January 2009 to December 2011. The identification and assessment
of DRPs were based on the Pharmaceutical Care Network Europe (PCNE) tool version 5.01. The potentially
inappropriate medication use in older adults was assessed based on the American Geriatrics Society updated
Beers Criteria.
Results: A total of 406 DRPs were identified. Among these patients, 91.8% had at least one DRP, averaging 1.94 ±
1.10 problems per patient. The majority of T2DM patients with dyslipidemia (91.8%) had at least one DRP. The
most frequent types of DRP were potential drug-drug interaction (18.0%), drug not taken or administered
(14.3%) and insufficient awareness of health and diseases (11.8%). Anti-hypertensive, lipid-modifying and
anti-diabetic agents were the drug classes that were most likely to be associated with DRPs. Male gender, renal
impairment, polypharmacy and poor lipid control were factors that were significantly associated with DRP in
diabetic dyslipidemia patients.
Conclusion: Early identification of DRPs and factors associated with them are essential to prevent and resolve
DRPs in T2DM patients with dyslipidemia.
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Dyslipidemia is a common co-morbidity in T2DM patients
[1]. According to the Center for Disease Control and Pre-
vention (CDC), 70% to 97% of T2DM adults have one or
more lipid abnormalities [2]. In T2DM patients, dyslipid-
emia is characterized by an elevated triglyceride (TG) level,
a decrease in high density lipoprotein cholesterol (HDL-C)
level and the presence of smaller and denser low density
lipoprotein cholesterol (LDL-C) particles [1,3].
Dyslipidemia in T2DM is associated with an increased
flux of free fatty acid release from insulin-resistant fat
cells to the liver. Consequently, the deposition of lipid in
blood vessels causes atherosclerotic lesions which later* Correspondence: hasnizazh@um.edu.my
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distribution, and reproduction in any mediumlead to cardiovascular disease (CVD) [3]. In addition, the
risk of coronary artery disease (CAD) in T2DM patients
increases 2- to 4-fold compared to non-diabetic patients [4].
The co-existence of dyslipidemia in T2DM patients will
further increase the risk of developing CAD [3,4].
Drug-related problems (DRPs) are pharmacotherapy
problems that actually or potentially have an impact on
desired health outcome [5]. There is a high prevalence of
DRP in T2DM patients, in which an average of about 4
DRPs occurred in a patient [6,7]. This is probably due to
patients receiving multiple drugs to control their medical
conditions, all of which promote DRPs. Several factors
could contribute to DRPs. For instance, liver or renal im-
pairment causes DRP via the alteration of the pharmaco-
kinetics of anti-diabetic and lipid-modifying agents [8,9].
In geriatrics, co-morbidities, poor medication adherence
and polypharmacy potentially cause DRPs [10,11].oMed Central Ltd. This is an open access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Zaman Huri and Chai Ling BMC Public Health 2013, 13:1192 Page 2 of 13
http://www.biomedcentral.com/1471-2458/13/1192Dyslipidemia and T2DM contribute substantially to car-
diovascular complications [3,4]; hence the optimization of
management by the identification and prevention of DRPs
is essential. There is a lack of studies on DRPs in T2DM pa-
tients with dyslipidemia, both locally and globally. There-
fore, this study aims to investigate DRPs in T2DM patients
with dyslipidemia and its objectives are to assess drug treat-
ment use, DRPs and factors affecting DRPs in T2DM pa-
tients with dyslipidemia. The findings from this study can
help to determine the pattern of DRPs in this population
and be used as preliminary data for future studies.
Methods
Study population and sampling frame
The study population consisted of all T2DM in-patients
and out-patients with dyslipidemia identified between
January 2009 and December 2011. The sample size was
calculated based on the Epi Info Program version 7.0 (CDC,
Clifton Rd. Atlanta, USA) with a minimum of 196 patients
to give a power of β= 0.8 and a confidence level of 95%.
Study design and procedures
The retrospective study was conducted in a tertiary teach-
ing hospital, namely the University of Malaya Medical
Centre (UMMC), Malaysia following approval by the
UMMC Ethics Committee. A total of 208 patients who
fulfilled the inclusion criteria (Table 1) were included in
this study (Figure 1). Table 2 shows the definitions that
were used in this study.
Identification of DRPs
The PCNE tool version 5.01 [5] was used to identify and
assess DRPs in this study. The assessment of DRPs was
based on each researcher’s clinical judgment with the
support of established literature and standard guidelines
of diseases [16,18-20].
Information on drugs, such as recommended dosages,
frequency, potential interactions and side-effects, was
based on the Drug Information Handbook [21] and theTable 1 Inclusion and exclusion criteria of the study
Inclusion criteria:
Adult patient above 18 years old and
(1) Diagnosed with T2DM and prescribed with at least
one anti-diabetic drug.
(2) Diagnosed with dyslipidemia and prescribed at least one LLA
Exclusion criteria:
(1) Patient with a disease other than T2DM.
(2) Diagnosed with dyslipidemia but not on
any pharmacological treatment.
(3) Patient prescribed with LLA but not diagnosed with any lipid disorders.
(4) Patient with incomplete dataBritish National Formulary [22]. The potentially inappro-
priate medication use in older adults was assessed based
on the American Geriatrics Society updated Beers Criteria
[12]. Table 3 and 4 shows definitions for DRPs and causes
associated with DRPs respectively.
Data analysis
All extracted data were pooled and analyzed using the
Statistical Package for the Social Sciences (SPSS) software
version 20.0 (SSPS Inc., Chicago, IL, USA). Continuous
data, such as A1C values and lipid profiles, were tested for
normality using the Kolmogorov-Smirnov test. A normally
distributed result was expressed as mean ± standard devi-
ation whilst the non-symmetrically distributed data was
presented as a median with the minimum and maximum
value. For categorical data, the Chi-squared test was used
to determine the association of patient’s characteristics and
the occurrence of DRP. When the expected cell count
for >20% was less than 5, Fisher’s Exact Test was used. On
the other hand, the T-test was used to compare mean be-
tween groups for continuous data. The statistical sig-
nificance was assumed at p < 0.05 in this study. The
summarized findings were rearranged and tabulated in
a graphical or table form.
Results
Demographic characteristics
A total of 208 T2DM patients fulfilled the inclusion criteria
in this study. Males (53.8%) are present in an almost equal
proportion as female patients in this study. The non-elderly
group of patients (56.7%) was slightly larger than the elderly
group. The mean ± standard deviation (SD) of patients’ age
was 61.7 ± 13.3 years old with the minimum and maximum
ages of 23 and 96 years old, respectively.
Clinical characteristics
The majority of the patient population had duration of
T2DM of less than or equal to 10 years (n = 137), and
most of the patients in this study were non-smokers
(66.4%). Results also showed that about 1 in 10 subjects
consumed alcohol (9.6%). Besides that, more than 70% of
subjects were found to have polypharmacy.
Hypertension contributed to the highest percentage
among all of the categories of co-morbidities. About a
quarter of renal impairment subjects (25.3%) were on
renal replacement therapy. There were only 5.8% (or 12
subjects) without any co-morbidity.
Metabolic control
There were only 49 subjects’ (23.6%) with an A1C value
within the targeted range (less than 6.5%). In this study,
the A1C values were not normally distributed. Hence, re-
sult was presented as median and range. Mean of A1C
value is 8.72 ± 0.19% in this study population. All of the
Registration Number (R/N) of all T2DM patients (fulfilled ICD-10 of 
E11) identified from January 2009 to December 2011 were identified 
using MMUS(514 patients)
Patients’ medical records were successfully 
retrieved from the Medical Records Office.
(404 patients)
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Figure 1 Overview of study procedure.
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and triglyceride were not normally distributed when tested
with normality test (refer Table 5).
About a quarter (24.5%) of the subjects had all lipid
parameters within the recommended range. The
remaining subjects had at least one lipid parameter that
was not within the normal range. Figure 2 shows the
lipid profiles of the subjects. Most of the patients were
unable to achieve the LDL-C and TG targeted levels,
which were <2.6 mmol/L and <1.7 mmol/L, respectively.Medication used in T2DM patients with dyslipidemia
The percentages of patients prescribed with combination
insulin therapy (24.5%), combination insulin and oral
hypoglycemic (OHA) therapy (24.0%), combination OHA
therapy (23.1%) and monotherapy of OHA (22.1%) were
about the same. Among the subjects, only 13 received
monotherapy of insulin. The most common anti-diabeticdrug prescribed in the study was metformin either as a
monotherapy or combination therapy (28.5%).
On the other hand, the most common lipid lowering
agent (LLA) prescribed in subjects was simvastatin
(151 subjects or 72.6%). There was only one subject
(0.5%) prescribed either rosuvastatin or pravastatin.
The mean number of chronic medications prescribed
per patient was 4.8 ± 3.3 medications. The two leading
concurrent chronic medications were anti-platelet
(65.4%) and ACE inhibitor (55.8%). Nevertheless, 11
subjects (5.3%) were not on any medication except for
anti-diabetic agents and LLA.
Drug-related problems
A total of 91.8% of patients (n = 191) had at least one
DRP. A total of 406 DRPs were identified and the mean
number of DRPs per patient was 1.94 ± 1.10. Out of 6
domains of DRP, 18 categories had at least one problem
reported. The identified DRPs were widely distributed,
Table 2 Definition of terms used in the study
Characteristics Definition References
Demographic 1) Elderly [12]
- Older adults above 64 years old
Co-morbidities 1) Cardiovascular accident (CVA) [1,13]
- Refers to stroke, transient ischemic attack and hemorrhagic stroke, ischemic heart disease (IHD)
2) Liver impairment
- Refers to chronic hepatitis, liver cirrhosis, fatty liver, elevation of liver enzyme such as alanine
transaminase (ALT) and aspartate transaminase (AST) of above 3 times upper limit of normal level
3) Renal impairment




- Refers to funduscopic deterioration or as stated in medical records.
2) Neuropathy
- For sensory, included history of foot lesions; for autonomic,
included sexual dysfunction and gastroparesis or as stated in medical records.
Metabolic control 1) Glycemic control [1,14-16]
- Good glycemic control refers to achieving targeted level of A1C <6.5%.
2) Lipid control
- Good lipid control refers to achieving all lipid fractions targeted level in which
LDL-C <2.6 mmol/L, TG <1.7 mmol/L and HDL-C >1.0 mmol/L.
- Poor lipid control refers to those patients unable to achieve one of the lipid fractions within targeted range.
Drug therapy 1) Polypharmacy [17]
- Six or more chronic medications for duration of at least one month.
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“drug not taken or administered at all” and “insufficient
awareness of health and diseases”. Table 6 reports the de-
tailed classifications of DRPs in 191 subjects.
The independent T-test showed that patients with DRPs
have significantly higher A1C values than those without
any DRPs (8.8% versus 7.4%, p = 0.004). However, there
was no significant difference between DRPs and the mean
of lipid fractions, which included total cholesterol (p =
0.247), LDL-C (p = 0.560), HDL-C (p = 0.092) and triglyc-
erides (p = 0.338).
A total of 491 causes associated with DRPs were iden-
tified among the 34 categories of PCNE classifications.Table 3 Definition of DRP classification
Code DRP Definition
P1 Adverse reactions Patient suffe
P2 Drug choice problem Patient gets
P3 Dosing problem Patient gets
P4 Drug use problem 1) Incorrect
2) No drug t
P5 Interactions There is a m
Adapted from: [5,22].The mean number of causes of DRP per patient was
2.37 ± 1.40. The three leading causes were “pharmaco-
kinetic problems”, “inappropriate dosage selection”
and “synergistic or preventive drug required and not
given”. Table 7 shows the causes associated with DRP
in 191 subjects.
There were 304 drugs that caused DRPs in subjects.
The drug class that was most likely to cause DRPs was
antihypertensive agents. This was followed by lipid-
lowering agents and anti-diabetic agents. Examples of
other medications include as warfarin, iron supplements
and glyceryl trinitrate. Different medication categories
that caused DRPs are shown in Figure 3.rs from an adverse drug event
or is going to get an incorrect (or no drug) drug for disease or condition
more or less than the amount of drug he or she requires
drug taken by patient
aken/administered for at least one dose of total daily dose
anifest or potential drug-drug or drug-food or drug-disease interaction
Table 4 Definition of causes associated with DRP
Code Primary domain Code Cause associated with DRP
C1 Drug/Dose selection C1.1 Inappropriate drug selection
The cause of the DRP is related to the selection of
the drug and/or dosage schedule
C1.2 Inappropriate dosage selection
C1.3 More cost effective drugs available
C1.4 Pharmacokinetic problems, incl. ageing/deterioration
in organ function and interactions
C1.5 Synergistic/preventive drug required and not given
C1.6 Deterioration/improvement of disease state
C1.7 New symptom or indication revealed/presented
C1.8 Manifest side effect, no other cause
C2 Drug use process C2.1 Inappropriate timing of administration and/or dosing intervals
The cause of the DRP can be related to the way the patient
uses the drug, in spite of proper dosage instructions (on the label)
C2.2 Drug underused/under-administered
C2.3 Drug overused/over-administered
C2.4 Therapeutic drug level not monitored
C2.5 Drug abused (unregulated overuse)
C2.6 Patient unable to use drug/form as directed
C3 Information C3.1 Instructions for use/taking not known
The cause of the DRP can be related to a lack
or misinterpretation of information
C3.2 Patient unaware of reason for drug treatment
C3.3 Patients has difficulties reading patient
information form/leaflet
C3.4 Patient unable to understand local language
C3.5 Lack of communication between
healthcare professionals
C4 Patient/Psychological C4.1 Patient forgets to use/take drug
The cause of the DRP can be related to
the personality or behavior of the patient.
C4.2 Patient has concerns with drugs
C4.3 Patent suspects side-effect
C4.4 Patient unwilling to carry financial costs
C4.5 Patient unwilling to bother physician
C4.6 Patient unwilling to change drugs
C4.7 Patient unwilling to adapt life-style
C4.8 Burden of therapy
C4.9 Treatment not in line with health beliefs
C4.10 Patient takes food that interacts with drugs
C5 Logistics C5.1 Prescribed drug not available (anymore)
The cause of the DRP can be related to the
logistics of the prescribing or dispensing mechanism
C5.2 Prescribing error (only in case of slip of the pen)
C5.3 Dispensing error (wrong drug or dose dispensed)
C5.1 Prescribed drug not available (anymore)
C6 Others C6.1 Other cause, specify
C6.2 No obvious cause
Total
Adapted from: [5,22].
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Table 5 Metabolic control of patients (n = 208)
Characteristics *Median Range
Minimum value Maximum value
A1C (%) 7.80 4.90 17.40
Lipid profile (mmol/L)
Total cholesterol 4.70 1.25 9.30
LDL-C* 2.68 0.27 7.34
HDL-C 1.08 0.02 2.52
Triglyceride 1.80 0.50 34.6
*LDL-C level was not calculated when TG ≥4.5 mmol/L based on the
UMMC’s Laboratory Information System (LIS).* Results were not
normally distributed.
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T2DM patients with dyslipidemia
Four factors (male gender, renal impairment, polyphar-
macy and lipid profile) were found to be significantly
associated with DRPs in T2DM patients with dyslipid-
emia (p <0.05). Males had more DRPs compared to
females. In addition, patients suffering from renal im-
pairment had a higher probability of having at least
one DRP compared to patients with normal renal
function.
There was also a significant difference in the patients
having polypharmacy compared to patients without
polypharmacy. Patients that were presented with more
than six drugs were at increased risk of the occurrence
of DRPs. On the other hand, patients with at least one
lipid parameter not within the targeted range had a
higher occurrence of DRP. Table 8 summarizes the fac-















Within normal range (%)
Figure 2 Lipid profiles of T2DM patients with dyslipidemia.Factors that were not significantly associated with DRP in
T2DM patients with dyslipidemia
Factors that were not significantly (p > 0.05) associated
with DRP in T2DM patients with dyslipidemia are shown
in Table 9.Discussion
Drug-related problems
The PCNE classification that was used in this study
has been critically appraised as the most appropriate
classification that reflects outcomes, and the results
are reproducible [23,24]. The classification tool has
been validated and was used in many other published
studies to assess DRP occurrence [10,24-26].
In this study, the mean of 2 DRPs per patient was less
than the levels found in previous studies, which were
about 4 DRPs per T2DM patient [6,7]. This could be
explained by the different DRP classification tool used,
which is more general compared to the PCNE tool. On
the other hand, the prevalence was high, with at least 9
out of 10 T2DM patients with dyslipidemia having
problems with drugs in this study. A study by Bob &
Ines [7] which used the same classification tool showed
that all T2DM patients had at least 1 DRP. The result
was significantly different as the methodology of the
studies was not the same. The assessment of DRP in
the current study solely depended on the review of
medical and biochemistry records. Meanwhile, Bob &
Ines [7] instilled a qualitative interview method in their
research to identify DRPs in T2DM patients. However,
the high occurrence of DRPs in this population of pa-
tients shows that there was lack of optimal pharmaco-





Not within normal range (%)
Table 6 Classification of DRP (N = 191)
Code Detailed classification n (%)
P1 Adverse reactions 31 (7.6)
P1.1 Side-effect suffered (non-allergic) 27 (6.6)
P1.2 Side-effect suffered (allergic) 4 (1.0)
P2 Drug choice problem 106 (26.1)
P2.1 Inappropriate drug (not most appropriate for indication) 27 (6.7)
P2.2 Inappropriate drug form (not most appropriate for indication) 1 (0.2)
P2.3 Inappropriate duplication of therapeutic group or active ingredient 9 (2.2)
P2.4 Contra-indication for drug (incl. Pregnancy/breast feeding) 15 (3.7)
P2.5 No clear indication for drug use 8 (2.0)
P2.6 No drug prescribed but clear indication 46 (11.3)
P3 Dosing problem 58 (14.3)
P3.1 Drug dose too low or dosage regime not frequent enough 41 (10.1)
P3.2 Drug dose too high or dosage regime too frequent 10 (2.5)
P3.3 Duration of treatment too short 6 (1.5)
P3.4 Duration of treatment too long 1 (0.2)
P4 Drug use problem 58 (14.3)
P4.1 Drug not taken/administered at all 58 (14.3)
P5 Interactions 73 (18.0)
P5.1 Potential interaction 73 (18.0)
P6 Others 80 (19.7)
P6.1 Patient dissatisfied with therapy despite taking drug(s) correctly 23 (5.7)
P6.2 Insufficient awareness of health and diseases (possibly leading to future problems) 48 (11.8)
P6.3 Unclear complaints. Further clarification necessary 2 (0.5)
P6.4 Therapy failure (reason unknown) 7 (1.7)
Total *406 (100.0)
*A patient may have one or more DRP. DRPs of code P1.3 (toxic effect suffered), P4.2 (wrong drug taken/administered at all) and P5.2 (manifest interaction) were
not listed in the table as none of the patients experienced these problems.
Zaman Huri and Chai Ling BMC Public Health 2013, 13:1192 Page 7 of 13
http://www.biomedcentral.com/1471-2458/13/1192The two most common DRP classifications identified
in the current study were “potential interaction” and
“drug not taken or administered at all”. These findings
were not in line with previous studies in T2DM popula-
tions conducted by Anne et al. [27] and Haugbolle et al.
[6]. Both of the studies reported “adverse drug reaction”
and “inappropriate use of medicines by the patients” as
the most common DRPs, respectively [6,27]. The fre-
quency of various drug categories varied among studies
as this depends on the methodology (such as medical re-
view or interview technique) and types of DRP classifica-
tion (such as PCNE or PI-Doc system) used.
Potential interaction
The high number of medications used and the combin-
ation of various drug classes contributed to the high
prevalence of significant potential drug-drug interactions
or drug-disease interactions in this population (17.5%).
This result was consistent with a study by Bob & Ines
[7] in which about 15% of potential drug interactionswere encountered. Nevertheless, the most common com-
bination drug was ACEI with sulfonylurea in the study by
Bob & Ines [7], whilst, in the current study, the combin-
ation of simvastatin and amlodipine contributed to the
highest number of potential drug-drug interactions. Other
significant potential drug interactions were the combin-
ation of antiplatelet and anticoagulant, and simvastatin
and fenofibrate, as well as other combinations.
Studies have shown that simvastatin serum concentra-
tions are significantly increased when used concurrently
with amlodipine [27-29]. This is due to the fact that both
simvastatin and amlodipine are substrates of CYP3A4.
Subsequently, in 2011, the Food and Drug Administra-
tion (FDA) released a safety announcement on the dose
limitation of 10 mg or 20 mg of simvastatin in order to
reduce the risk of myopathy [30]. This alert has had a
great impact on drug and dose selection in the manage-
ment of T2DM patients with dyslipidemia as CCB was
commonly prescribed (41%) to this group of patients. In
the current study, it has been found that prescribers in
Table 7 Causes associated with DRP (N = 191)
Code Detailed classification n (%)
C1 Drug/Dose selection 277 (56.5)
C1.1 Inappropriate drug selection 36 (7.3)
C1.2 Inappropriate dosage selection 69 (14.1)
C1.4 Pharmacokinetic problems, incl. ageing/deterioration in organ function and interactions 84 (17.1)
C1.5 Synergistic/preventive drug required and not given 48 (9.8)
C1.6 Deterioration/improvement of disease state 11 (2.2)
C1.7 New symptom or indication revealed/presented 12 (2.4)
C1.8 Manifest side effect, no other cause 17 (3.6)
C2 Drug use process 22 (4.4)
C2.1 Inappropriate timing of administration and/or dosing intervals 6 (1.2)
C2.2 Drug underused/under-administered 5 (1.0)
C2.3 Drug overused/over-administered 3 (0.6)
C2.4 Therapeutic drug level not monitored 3 (0.6)
C2.5 Drug abused (unregulated overuse) 3 (0.6)
C2.6 Patient unable to use drug/form as directed 2 (0.4)
C3 Information 31 (6.4)
C3.1 Instructions for use/taking not known 17 (3.6)
C3.2 Patient unaware of reason for drug treatment 5 (1.0)
C3.4 Patient unable to understand local language 7 (1.4)
C3.5 Lack of communication between healthcare professionals 2 (0.4)
C4 Patient/Psychological 140 (28.5)
C4.1 Patient forgets to use/take drug 36 (7.3)
C4.2 Patient has concerns with drugs 11 (2.2)
C4.3 Patent suspects side-effect 3 (0.6)
C4.4 Patient unwilling to carry financial costs 8 (1.6)
C4.5 Patient unwilling to bother physician 14 (2.9)
C4.6 Patient unwilling to change drugs 1 (0.2)
C4.7 Patient unwilling to adapt life-style 45 (9.2)
C4.8 Burden of therapy 1 (0.2)
C4.9 Treatment not in line with health beliefs 19 (3.9)
C4.10 Patient takes food that interacts with drugs 2 (0.4)
C5 Logistics 18 (3.6)
C5.1 Prescribed drug not available (anymore) 8 (1.6)
C5.2 Prescribing error (only in case of slip of the pen) 8 (1.6)
C5.3 Dispensing error (wrong drug or dose dispensed) 2 (0.4)
C6 Others 3 (0.6)
C6.2 No obvious cause 3 (0.6)
Total *491 (100.0)
*A DRP associated with one or more causes. Causes of code C1.3 (More cost-effective drug available), C3.3 (Patient has difficulties reading/understanding Patient
Information Form/Leaflet) and C6.1 (Other cause) were not listed in the table as none of the DRPs were associated with these causes.
Zaman Huri and Chai Ling BMC Public Health 2013, 13:1192 Page 8 of 13
http://www.biomedcentral.com/1471-2458/13/1192the UMMC were not aware of the dose limitation issues,
as about 10% of the sample subjects were given high dose
simvastatin even though they were also prescribed CCB
(amlodipine, diltiazem and verapamil) concurrently.Drug not taken/administered
Poor medication adherence was the second most common
DRP (14.3%) found in this study [7,10,31]. This is in agree-


















Figure 3 Medication categories that causes drug-related problems; * LLA refers to lipid-lowering agents.
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[7]. This study also revealed that the non-adherence pa-
tients had significantly higher A1C values as compared to
the compliant patients (9.7% versus 8.4%, p = 0.01). The
significant relationship was in agreement with the study
by Bob & Ines [7] (A1C of 9.4% versus 8.4%; p = 0.01). In
addition, this study also showed a significant association
between compliance issues and poor lipid control (p =
0.002). This critical finding indicated the importance of
compliance to anti-diabetic and LLA drugs in T2DM pa-
tients with dyslipidemia in order to achieve better gly-






Male 5.583 108 (96.4%) 4 (3.6%) 0.011
Female 83 (86.5%) 13 (13.5%)
Renal impairment
Yes 5.596 85 (97.7%) 2 (2.3%) 0.009
No 106 (87.6%) 15 (12.4%)
Polypharmacy
Yes 4.264 141 (94.6%) 8 (5.4%) 0.039
No 50 (84.7%) 9 (15.3%)
Lipid control
Good lipid control 9.840 41 (80.4%) 10 (19.6%) 0.002
Poor lipid control 150 (95.5%) 7 (4.5%)
*DRP reported as the number of patients (percentage across row,%); δdegrees
of freedom = 1.More than 90% of poor medication compliance cases in
this study were due to the patients forgetting to take medi-
cines. This result is in accordance with a study by Lorenzo
et al. [31]. Other reasons detected in this study were that
patients had concerns over drugs due to their side-effects
or the fact that they were unable to purchase medications
from community pharmacy. Nevertheless, the findings
were dependent on the honesty of the patient’s self-
reporting compliance and the availability of data in the
medical reports.
In contrast, Chan et al. [10] reported a much higher per-
centage of the same type of DRP in the geriatric popula-
tion (35%). The explanation was most probably due to
polypharmacy and a decrease in cognitive memory func-
tion in the geriatric patients [10].
Causes associated with drug-related problems
Pharmacokinetic problems (code C1.4) were the most
frequent causes associated with DRPs. Age-associated
physiological changes leading to alteration of the phar-
macokinetic and pharmacodynamic properties of drugs
were one of the main contributors that caused DRPs
[10]. In contrast, the current study (p = 0.662) found that
there was no significant association between age and
DRPs, which was in line with previous results [32].
In addition, drug-drug interactions that cause alter-
ations in the pharmacokinetics of drugs also contrib-
uted to the high percentage of this DRP. For example,
the concurrent use of simvastatin and amlodipine,
which are both metabolized by the liver enzyme
CYP3A4, causes a decrease in the metabolism rate
of simvastatin [21,30]. Thus, healthcare providers
should focus more attention on the alterations of
Table 9 Parameters that were not significantly associated with DRP
Characteristics n Number of patients (percentage,%) p Value
Age
Non-elderly (18-64 years old) 208 118 (56.7) 0.662b
Elderly (≥65 years old) 90 (43.3)
Ethnicity
Malay 208 90 (43.3)




≤10 years 137 79 (57.7)
11-20 years 30 (21.9) 0.442a
21-30 years 20 (14.6)
≥31 years 8 (5.8)
Smoking habit








Neuropathy 208 19 (9.1) 0.192c
Retinopathy 208 50 (24.0) >0.999c
Co-morbidities
Hypertension 208 167 (80.3) 0.465b
CVA 208 41 (19.7) >0.999c
IHD 208 69 (33.2) 0.188c
Liver impairment 208 23 (11.1) >0.999c
Thyroid disorder 208 10 (4.8) >0.999c
Others 208 87 (41.8) >0.999b
Glucose control
A1C less than 6.5% 208 49 (23.6%) 0.137b
A1C more or equal than 6.5% 159 (76.4%)
aPearson Chi Squared Test; bContinuity Correction; cFisher Exact Test.
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physiological factors or concurrent drug use. Changes
in doses or shifting to alternative drugs may be required
if the alteration of pharmacokinetics leads to significant
adverse effect [21].
Under-dosing or overdosing in about 15% of T2DM
patients with dyslipidemia was the second highest
cause that was associated with DRP in this study. Non-
optimal dosing in anti-diabetic and LLA drugs were
the two most frequent causes of dosing problems (codeC1.2) in this population of patients. A study by Bob &
Ines [7] showed contrasting results, in which only 5.9%
of the T2DM patients had dosing problems. The dis-
crepancy may be explained by a more general group of
T2DM patients who participated in a Pharmacy Dia-
betes Care Programme in Australia. Hence, this might
not represent the most appropriate data of T2DM pa-
tients with dyslipidemia. From this study, it was shown
that optimal dosing of both anti-diabetic and LLA can
prevent DRP from occurring.
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A quarter of patients had problems with antihypertensive
agents in this study. This was followed by lipid-lowering
agents (24.0%) and anti-diabetic agents (21.7%). This could
be due to the fact that antihypertensive agents were pre-
scribed to at least 80% of patients in this study. Combina-
tions of antihypertensive agents are required in order to
maintain the blood pressure level below 130/80 mmHg or
125/75 mmHg with proteinuria of more than 1 g/24 hours
[1,18,19]. Thus, there was a higher possibility to develop
DRPs secondary to the wide range of use of antihyperten-
sive drugs. However, this study found that the use of anti-
hypertensive agents was not significantly associated with
an occurrence of DRP in T2DM patients with dyslipid-
emia (p = 0.465). This may be due to the small sample size
of patients that had DRP secondary to antihypertensive
agents in which random chance cannot be eliminated.
Factors that were significantly associated with
drug-related problems
Gender
In this study, a significant statistical difference was de-
tected between gender and the occurrence of DRP. Male
patients had a higher chance (96.4%) of having DRPs com-
pared to female patients (86.5%). To date, there is a lack of
studies focusing on the association of DRP with gender.
However, a study by Babwah et al. in 2006 [33] reported
that women who are unemployed have more time to at-
tend clinic appointments and tend to be more compliant
in terms of diet and medication when compared to men
[33,34]. On the other hand, men who work and practice
unhealthy habits, such as drinking alcohol and smoking,
have a higher probability of having DRPs [33,34]. To date,
there is a lack of evidence to suggest that biological factors
associated with gender may affect the pharmacological
treatment. Besides, in this study, the higher proportion of
males compared to female patients may lead to the ran-
dom chance of males having at least one DRP.
Renal impairment
Renal impairment showed a significant association with the
occurrence of DRP in this study. A high percentage (about
98%) of diabetic dyslipidemia patients with renal impair-
ment had at least one DRP. Evidences suggested that renal
impairment patients require more pharmaceutical interven-
tion as DRPs commonly occurred in all healthcare settings
[9,35]. Similarly, this study found that DRPs of potential
drug interaction (18.9%), untreated conditions such as
anemia (10.8%) and poor medication compliance (10.8%)
frequently occurred in diabetic dyslipidemia patients with
chronic kidney disease.
The inappropriate use of renal risk drugs has been con-
troversial in T2DM patients with dyslipidemia [35,36]. In
long-term treatment, renal risk drugs, such as ACEI,calcium channel blockers and simvastatin, are in fact reno-
protective drugs. These medications can decrease microal-
buminuria, slow the progression to end stage renal failure
and prevent cardiovascular events in high risk patients, es-
pecially T2DM patients with dyslipidemia [35,36]. A study
has been proposed to examine the role of lipid control by
statins in the prevention of nephropathy, as well as the
additional effect of reducing proteinuria [37]. Therefore, it
is recommended to use these drugs in caution with close
monitoring for dosing adjustment due to the risk of caus-
ing DRPs in this population of patients.
Polypharmacy
The issue of polypharmacy is commonly reported as a risk
factor that contributes to the occurrence of DRPs in differ-
ent study subjects [32,38,39]. In agreement with a few
studies, polypharmacy was shown to be significantly asso-
ciated with DRP in T2DM patients with dyslipidemia, in
which about 95% of patients with six or more drugs had at
least one DRP [32,38,39]. Polypharmacy has been associ-
ated with problems such as poor medication adherence,
potential drug-drug interactions and side-effects of drugs
[38,39]. Patients with multiple drug classes of medicines
often have a complex drug schedule. The frequent daily
drug administration and different pill numbers for each
medication may contribute to the poor medication adher-
ence problem in these patients38. A recent study showed
that DRPs secondary to polypharmacy will lead to the in-
creased cost of treatment and hospitalization [32]. However,
the under-treatment of disease by reducing the number of
drugs may cause more serious consequences, especially in
T2DM patients with dyslipidemia [39]. Hence, pharmacists
play an important role in the optimization of drug treat-
ment for the patient’s benefit.
Lipid control
The ability to achieve good control of lipid levels was
shown to have a statistically significant association with the
occurrence of DRP in T2DM patients with dyslipidemia.
Poor lipid control in this study was defined as when at least
one lipid parameter was not within the targeted range ac-
cording to the ADA recommendations [1]. The current
study showed that patients with poor lipid control were at
a higher risk of developing DRPs (95.5%). This can be ex-
plained by the fact that patients with poor lipid control are
at an increased risk of developing macrovascular complica-
tions, such as atherosclerosis, myocardial infarction, hyper-
tension and stroke [1,3]. Theoretically, the development
and progression of complications lead to more drugs being
used in order to control the complications [4,38]. Thus,
this increases the probability of DRP occurrence.
In addition, poor lipid control may induce the develop-
ment and progression of nephropathy by releasing media-
tors, such as cytokines and reactive oxygen species, that
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gression of nephropathy secondary to poor lipid control
may increase the probability of DRPs occurring. This sug-
gestion is in line with the findings of the current study, in
which nephropathy was significantly associated with DRP
occurrence (p = 0.009). Therefore, a strict lipid control ap-
proach is important in T2DM patients with dyslipidemia.
A poor lipid profile may enhance the development of
microvascular and macrovascular complications that sub-
sequently lead to the occurrence of DRPs.
The identification of underlying factors associated with
DRPs may help in preventing and resolving DRPs in
T2DM patients with dyslipidemia.
Therefore, the early identification of DRPs and factors
associated with them may help to prevent and resolve
DRPs in T2DM patients with dyslipidemia and thus en-
hance the most appropriate drug treatment and a more
cost-effective pharmaceutical care.
Study limitation
The retrospective nature of study design limits the infor-
mation source in which the assessment of DRP was solely
dependent on the medical records and biochemistry data
from Laboratory Information System. Besides, lack of
standard tools to recognise DRP in T2DM patients limits
the comparison of DRPs with other studies.
Conclusion
Potential drug interactions, poor medication adherence
and the lack of health consciousness were the three most
common factors found in this study. Factors associated
with DRPs in T2DM patients with dyslipidemia were male
gender, renal impairment, polypharmacy and poor lipid
control.
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